13F filer · CIK 2092021
Seven Fleet Capital Management LP
MOUNTAIN VIEW, CA · filing since Q4 2025 · last filing Aug 17, 2026
Reported value
$605.9M
+$287.7M vs prior
Positions
96
New / sold out
24 / 43
Added / reduced
43 / 22
Turnover
40.6%
buys $436.3M · sells $187.5M
Top-10 weight
65.1%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | CG ONCOLOGY INC | +1,810,478 | +2389.8% | +$128.6M |
| Added | TANGO THERAPEUTICS INC | +2,726,132 | +543.0% | +$80.8M |
| Added | REVOLUTION MEDICINES INC | +161,237 | +199.6% | +$30.2M |
| Added | PHARVARIS N V | +601,770 | +348.4% | +$20.8M |
| New | MIRUM PHARMACEUTICALS INC | +110,393 | – | +$12.9M |
| Added | ASSEMBLY BIOSCIENCES INC | +377,000 | +671.5% | +$10.4M |
| Added | AVALO THERAPEUTICS INC | +556,946 | +260.5% | +$10.3M |
| Added | ENLIVEN THERAPEUTICS INC | +201,356 | +122.8% | +$10.2M |
| New | VERADERMICS INC | +80,000 | – | +$9.8M |
| Added | ABIVAX SA | +68,282 | +158.6% | +$9.1M |
57 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | CG ONCOLOGY INC | -1,439,393 | -100.0% | $-97.4M |
| Sold out | TYRA BIOSCIENCES INC | -195,685 | -100.0% | $-7.5M |
| Sold out | TANGO THERAPEUTICS INC | -300,648 | -100.0% | $-6.3M |
| Reduced | AGIOS PHARMACEUTICALS INC | -152,647 | -72.8% | $-5.7M |
| Sold out | AVALO THERAPEUTICS INC | -360,064 | -100.0% | $-5.4M |
| Sold out | MINERVA NEUROSCIENCES INC | -889,254 | -100.0% | $-5.4M |
| Reduced | VAXCYTE INC | -78,650 | -72.5% | $-4.7M |
| Sold out | PHARVARIS N V | -143,966 | -100.0% | $-4.1M |
| Sold out | SOLENO THERAPEUTICS INC | -115,770 | -100.0% | $-3.9M |
| Sold out | ENLIVEN THERAPEUTICS INC | -95,253 | -100.0% | $-3.7M |
55 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | CG ONCOLOGY INCCOM | 1,886,236 | $134.0M | 22.12% |
| 2 | TANGO THERAPEUTICS INCCOM | 3,228,144 | $95.7M | 15.79% |
| 3 | REVOLUTION MEDICINES INCCOM | 242,029 | $45.3M | 7.48% |
| 4 | PHARVARIS N VCOM | 774,501 | $26.8M | 4.42% |
| 5 | LIQUIDIA CORPORATIONCOM NEW | 256,603 | $20.5M | 3.38% |
| 6 | ENLIVEN THERAPEUTICS INCCOM | 365,386 | $18.5M | 3.06% |
| 7 | ABIVAX SASPONSORED ADS | 111,334 | $14.8M | 2.45% |
| 8 | AVALO THERAPEUTICS INCCOM NEW | 770,765 | $14.2M | 2.35% |
| 9 | MIRUM PHARMACEUTICALS INCCOM | 110,393 | $12.9M | 2.13% |
| 10 | ASSEMBLY BIOSCIENCES INCCOM NEW | 433,147 | $11.9M | 1.96% |
86 more rows. Subscribe for $29/month to see every row, download the data and use the API.